Astria Therapeutics, Inc. lost $1.68 per diluted share in fiscal year 2024. Over the trailing 12 months, Q4 FY2024 through Q3 FY2025, the same line adds up to a loss of $2.14 per diluted share. The table below carries 12 fiscal years, from 2013 to 2024, and the quarters Astria Therapeutics, Inc. has filed alongside them.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
What was Astria Therapeutics, Inc.'s diluted earnings per share in fiscal year 2024?
Astria Therapeutics, Inc. lost $1.68 per diluted share in fiscal year 2024.
What is Astria Therapeutics, Inc.'s diluted earnings per share over the last twelve months?
Astria Therapeutics, Inc. (ATXS) reported a loss of $2.14 per diluted share over the trailing 12 months, Q4 FY2024 through Q3 FY2025, summed from the four most recent quarterly filings.
What was Astria Therapeutics, Inc.'s diluted earnings per share in the most recent quarter?
Astria Therapeutics, Inc. (ATXS) reported -$0.55 in diluted earnings per share in Q3 2025. This represents a decrease of 31.0% from the same quarter a year earlier.
What does diluted earnings per share mean on a financial statement?
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Astria Therapeutics, Inc. (ATXS) reported on that line in every period on record.
